 | Up a level |
Broeckelmann, Paul J., Buehnen, Ina, Meissner, Julia, Trautmann-Grill, Karolin, Herhaus, Peter, Halbsguth, Teresa, V, Schaub, Valdete, Kerkhoff, Andrea, Mathas, Stephan, Bormann, Matthias, Dickhut, Andreas, Kaul, Helen, Fuchs, Michael, Kobe, Carsten, Baues, Christian, Borchmann, Peter, Engert, Andreas and von Tresckow, Bastian (2022). Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial. Blood, 140. S. 1753 - 1756. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Eichenauer, Dennis A. 
ORCID: 0000-0002-1927-3514, Buehnen, Ina, Pluetschow, Annette, Kobe, Carsten, Dietlein, Markus, Wendtner, Clemens-Martin, Thorspecken, Sven, Topp, Max S., Mauser, Mareike, von Tresckow, Bastian, Fuchs, Michael, Borchmann, Peter and Engert, Andreas
(2022).
Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group.
Hematol. Oncol., 40 (4).
S. 801 - 805.
HOBOKEN:
WILEY.
ISSN 1099-1069
Kreissl, Stefanie, Voltin, Conrad-Amadeus ORCID: 0000-0002-5437-3959, Kaul, Helen, Buehnen, Ina, Mettler, Jasmin, Pabst, Thomas, Eichenauer, Dennis A. ORCID: 0000-0002-1927-3514, Fuchs, Michael, Diehl, Volker, Dietlein, Markus, Engert, Andreas, Borchmann, Peter and Kobe, Carsten
.
Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma.
Br. J. Haematol..
HOBOKEN:
WILEY.
ISSN 1365-2141
Momotow, Jesko, Buehnen, Ina, Trautmann-Grill, Karolin, Kobbe, Guido, Hahn, Dennis, Schroers, Roland ORCID: 0000-0003-2744-5491, Heinrich, Bernhard, Gaska, Tobias, Forstbauer, Helmut, Schmidt, Burkhard, Boger, Regina, Huettmann, Andreas, Heil, Gerhard, Kraemer, Doris M., Krueger, William, Zeremski, Vanja, Grobe, Norbert, Jentsch-Ullrich, Kathleen, Griesinger, Frank, Fuchs, Michael, von Tresckow, Bastian, Borchmann, Peter, Engert, Andreas and Broeckelmann, Paul J.
(2022).
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis.
Br. J. Haematol., 198 (2).
S. 401 - 405.
HOBOKEN:
WILEY.
ISSN 1365-2141